These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

608 related articles for article (PubMed ID: 21354954)

  • 1. [Pharmacologic therapy for neuroendocrine tumours].
    Petrányi A; Bodoky G
    Orv Hetil; 2011 Mar; 152(10):379-91. PubMed ID: 21354954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pancreatic neuroendocrine tumors: targeting the molecular basis of disease.
    Khagi S; Saif MW
    Curr Opin Oncol; 2015 Jan; 27(1):38-43. PubMed ID: 25390554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic treatment of neuroendocrine tumors with hepatic metastases.
    Demirkan BH; Eriksson B
    Turk J Gastroenterol; 2012; 23(5):427-37. PubMed ID: 23161287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors.
    Raj N; Reidy-Lagunes D
    Hematol Oncol Clin North Am; 2016 Feb; 30(1):119-33. PubMed ID: 26614372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours.
    Van Essen M; Krenning EP; De Jong M; Valkema R; Kwekkeboom DJ
    Acta Oncol; 2007; 46(6):723-34. PubMed ID: 17653893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Drug therapy for neuroendocrine tumours].
    Tóth M
    Orv Hetil; 2013 Sep; 154(39):1556-64. PubMed ID: 24058101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Carcinoid tumors].
    Pregun I; Bodoky G; Rácz K; Tulassay Z
    Orv Hetil; 2010 Nov; 151(46):1885-94. PubMed ID: 21044939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of somatostatin analogues in the treatment of neuroendocrine tumours.
    Grozinsky-Glasberg S; Grossman AB; Korbonits M
    Mol Cell Endocrinol; 2008 May; 286(1-2):238-50. PubMed ID: 18037561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas.
    Fazio N; Cinieri S; Lorizzo K; Squadroni M; Orlando L; Spada F; Maiello E; Bodei L; Paganelli G; Delle Fave G; de Braud F
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S87-94. PubMed ID: 21129617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical treatment of neuroendocrine tumours.
    Weber HC
    Curr Opin Endocrinol Diabetes Obes; 2013 Feb; 20(1):27-31. PubMed ID: 23221494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
    Chan HY; Grossman AB; Bukowski RM
    Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic Therapies for Advanced Gastrointestinal Carcinoid Tumors.
    Mulvey CK; Bergsland EK
    Hematol Oncol Clin North Am; 2016 Feb; 30(1):63-82. PubMed ID: 26614369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New perspectives in the treatment of neuroendocrine tumours.
    Bajetta E; Catena L; Valente M; Bianco N; Bellomo F; Bombardieri E
    Anticancer Res; 2012 Oct; 32(10):4193-200. PubMed ID: 23060539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours.
    Oberg K
    Ann Oncol; 2001; 12 Suppl 2():S111-4. PubMed ID: 11762335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current clinical trials of targeted agents for well-differentiated neuroendocrine tumors.
    Raj N; Reidy-Lagunes D
    Pancreas; 2014 Nov; 43(8):1185-9. PubMed ID: 25333401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New treatment strategies in advanced neuroendocrine tumours.
    Walter T; Brixi-Benmansour H; Lombard-Bohas C; Cadiot G
    Dig Liver Dis; 2012 Feb; 44(2):95-105. PubMed ID: 21983252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy.
    Leung R; Lang B; Wong H; Chiu J; Yat WK; Shek T; Cho WY; Yau LC; Yau T
    Anticancer Agents Med Chem; 2013 Mar; 13(3):382-8. PubMed ID: 23092266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
    Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP
    Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors.
    Faivre S; Sablin MP; Dreyer C; Raymond E
    Endocrinol Metab Clin North Am; 2010 Dec; 39(4):811-26. PubMed ID: 21095547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors.
    Naraev BG; Strosberg JR; Halfdanarson TR
    Oncology; 2012; 83(3):117-27. PubMed ID: 22797357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.